Sorrento Therapeutics (SRNEQ) Stock Price, News & Analysis

0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
50-Day Range
52-Week Range
198,999 shs
Average Volume
511,766 shs
Market Capitalization
$11.03 million
P/E Ratio
Dividend Yield
Price Target
SRNEQ stock logo

About Sorrento Therapeutics Stock (OTCMKTS:SRNEQ)

Sorrento Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company specializes in developing antibody-based therapies for cancer, autoimmune diseases, and chronic pain. Sorrento Therapeutics was founded in 1989 and has since grown into a  player in the biopharmaceutical industry, focusing on developing innovative and personalized therapies for patients.

The management team at Sorrento Therapeutics is led by Dr. Henry Ji, who serves as the company's Chairman and CEO. Dr. Ji has over 20 years of experience in the biopharmaceutical industry and has played a vital role in developing innovative Sorrento Therapeutics therapies. Other notable team members are Mike Royal, Chief Medical Officer, who has over 20 years of clinical development experience and Dr. Robert D. Allen, who has over 15 years of biotechnology industry research and preclinical development experience. 

Over the past few years, Sorrento Therapeutics has reported relevant growth in revenue. However, the company has also reported significant losses increasing year over year. The company's debt levels have varied dramatically, with assets and liabilities increasing year over year. Sorrento Therapeutics has undergone substantial changes in ownership over the past few years, with several prominent investors increasing their stakes in the company. Sorrento Therapeutics' valuation metrics align with industry peers, with a price-to-book ratio near industry averages. However, the company's price-to-earnings ratio is currently negative, typical for clinical-stage biopharmaceutical companies that have yet to reach profitability. Sorrento Therapeutics stock has been volatile in recent years, with significant price movements and changes in trading volume. The company's stock price has steadily declined over the past five years.

The biopharmaceutical industry is highly competitive, with many large, established companies and smaller, innovative players like Sorrento Therapeutics. High research and development spending levels, lengthy regulatory approval processes, and significant intellectual property protections characterize the industry. Sorrento Therapeutics faces competition from established players such as Pfizer, Merck, and Bristol-Myers Squibb, as well as smaller biotechs developing similar antibody-based therapies.

Sorrento Therapeutics has several potential growth opportunities, including developing its proprietary antibodies and other therapies for treating cancer, autoimmune diseases, and chronic pain. The company is also exploring partnerships and collaborations with other companies in the biopharmaceutical industry to help accelerate the development of its pipeline of therapies. Additionally, Sorrento Therapeutics is expanding into new markets, focusing on Asia, with significant demand for innovative treatments.

The biopharmaceutical industry is highly regulated, and Sorrento Therapeutics may face challenges in obtaining regulatory approval for its therapies. The company's financial performance has also been volatile, with significant losses reported in recent years. Sorrento Therapeutics will need to continue investing heavily in research and development to maintain its competitive position in the industry, which may strain the company's financial resources. In addition, the biopharmaceutical industry is subject to significant geopolitical and regulatory risks, which could impact Sorrento Therapeutics' operations and growth prospects.

SRNEQ Stock Price History

SRNEQ Stock News Headlines

The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Sorrento Therapeutics Inc. (SRNEQ)
See More Headlines
Receive SRNEQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$62.84 million
Book Value
($0.05) per share


Free Float
Market Cap
$11.03 million
Not Optionable
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Henry H. Ji Ph.D. (Age 60)
    Chairman, President & CEO
    Comp: $2.03M
  • Dr. Alexis Nahama D.V.M.
    Senior Vice President of Neurotherapeutics BU
  • Dr. Mark R. Brunswick
    Senior Vice President of Regulatory Affairs
  • Dr. Shawn Sahebi Ph.D.
    Senior Vice President of Commercial Operations
  • Dr. Xiao Xu M.D.
    President of ACEA

SRNEQ Stock Analysis - Frequently Asked Questions

How have SRNEQ shares performed in 2024?

Sorrento Therapeutics' stock was trading at $0.1235 at the beginning of 2024. Since then, SRNEQ shares have decreased by 83.8% and is now trading at $0.02.
View the best growth stocks for 2024 here

When is Sorrento Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SRNEQ earnings forecast

How do I buy shares of Sorrento Therapeutics?

Shares of SRNEQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SRNEQ) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners